Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STELLAR: High-dose Sunitinib in Recurrent Glioblastoma
NCT03025893Phase 3Unknown
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2018
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sunitinib in glioblastoma multiforme (GBM), sponsored by Amsterdam University Medical Center. Status: unknown.
02
Drugs
sunitinib
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT03025893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03025893.